<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="24f87fb8-dc5d-4daf-8afc-047afe1bcfee"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use VIVIMUSTA safely and effectively. See full prescribing information for VIVIMUSTA.<br/>
      <br/> VIVIMUSTA® (bendamustine hydrochloride injection), for intravenous use.<br/> Initial U.S. Approval: 2008<br/>
   </title>
   <effectiveTime value="20250403"/>
   <setId root="4df6548f-c4ad-4eb2-a54f-19766a3d90ca"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="117505635"/>
            <name>Azurity Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="339062883" root="1.3.6.1.4.1.519.1"/>
                        <name>Latina Pharma S.p.A.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="24338-270" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="24338-270" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="24338-270" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="5b807241-f009-4229-9a46-63c9c145ce2f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250331"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="24338-270" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>VIVIMUSTA<suffix/>
                        </name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>BENDAMUSTINE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="25" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="981Y8SX18M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENDAMUSTINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9266D9P3PQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BENDAMUSTINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="AAO1P0WSXJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MONOTHIOGLYCEROL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="4" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="24338-270-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250401"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA212209" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250401"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW">
                              <originalText>colorless to yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="263d554e-c837-4564-99b0-660122522e02"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS &amp; USAGE</title>
               <effectiveTime value="20250328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>VIVIMUSTA is an alkylating drug indicated for treatment of patients with:<br/> • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. (<linkHtml href="#Section_1.1">1.1</linkHtml>)<br/> • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. (<linkHtml href="#Section_1.2">1.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_1.1">
                     <id root="f391ea16-c2a2-4b31-9071-e0878796cdc1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.1 Chronic Lymphocytic Leukemia (CLL)</title>
                     <text>
                        <paragraph>VIVIMUSTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.2">
                     <id root="d04972b7-2537-4c65-bf86-eca867da686b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.2 Non-Hodgkin Lymphoma (NHL)</title>
                     <text>
                        <paragraph>VIVIMUSTA is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="dc585047-59ad-4577-be74-4ad0f3300a1d"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE &amp; ADMINISTRATION</title>
               <effectiveTime value="20250328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">For CLL</content>:<br/> • 100 mg/m<sup>2</sup> infused intravenously over 20 minutes on Days 1 and 2 of a 28­ day cycle, up to 6 cycles (<linkHtml href="#Section_2.1">2.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">For NHL</content>:<br/> • 120 mg/m<sup>2</sup> infused intravenously over 20 minutes on Days 1 and 2 of a 21­ day cycle, up to 8 cycles (<linkHtml href="#Section_2.2">2.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="e1d1a471-494a-4ce3-85ff-aa9ac16331f5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.1 Dosing Instructions for CLL</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage</content>
                           <br/> The recommended dosage is 100 mg/m<sup>2</sup> administered intravenously over 20 minutes on Days 1 and 2 of a 28-day cycle for up to 6 cycles.<br/>
                           <br/>
                           <content styleCode="underline">Dose Delays, Dose Modifications and Re-initiation of Therapy for CLL</content>
                           <br/> Delay VIVIMUSTA for Grade 4 hematologic toxicity or clinically significant Grade 2 or greater non-hematologic toxicity. <br/>
                           <br/> Once non-hematologic toxicity has recovered to less than or equal to Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L], reinitiate VIVIMUSTA at the discretion of the healthcare provider. In addition, consider dose reduction [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>
                           </content>)]<br/>
                           <br/> Dose modifications for hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 50 mg/m<sup>2</sup> on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 25 mg/m<sup>2</sup> on Days 1 and 2 of each cycle.<br/>
                           <br/> Dose modifications for non-hematologic toxicity: for clinically significant Grade 3 or greater toxicity, reduce the dose to 50 mg/m<sup>2</sup> on Days 1 and 2 of each cycle.<br/>
                           <br/> Consider dose re-escalation in subsequent cycles at the discretion of the healthcare provider.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="0845561f-3f60-44c3-89b9-5ed843ef8af3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.2 Dosing Instructions for NHL</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage</content>
                           <br/> The recommended dosage is 120 mg/m<sup>2</sup> administered intravenously over 20 minutes on Days 1 and 2 of a 21-day cycle for up to 8 cycles.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dose Delays, Dose Modifications and Re-initiation of Therapy for NHL</content>
                           <br/> Delay VIVIMUSTA for Grade 4 hematologic toxicity or clinically significant Grade 2 or greater non-hematologic toxicity. <br/>
                           <br/> Once non-hematologic toxicity has recovered to less than or equal to Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L], reinitiate VIVIMUSTA at the discretion of the healthcare provider. In addition, consider dose reduction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>
                           <br/>
                           <br/> Dose modifications for hematologic toxicity: for Grade 4 toxicity, reduce the dose to 90 mg/m<sup>2</sup> on Days 1 and 2 of each cycle; if Grade 4 toxicity recurs, reduce the dose to 60 mg/m<sup>2</sup> on Days 1 and 2 of each cycle.<br/>
                           <br/> Dose modifications for non-hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 90 mg/m<sup>2</sup> on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m<sup>2</sup> on Days 1 and 2 of each cycle.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="d0d2b732-6607-4c25-9726-63186733be7f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.3 Preparation and Administration</title>
                     <text>
                        <br/>
                        <paragraph> VIVIMUSTA is a hazardous drug. Follow applicable special handling and disposal procedures.<sup>1</sup>
                           <br/>
                           <sup> </sup>VIVIMUSTA is a clear and colorless to yellow solution in a multiple-dose vial.</paragraph>
                        <br/>
                        <paragraph> Store VIVIMUSTA refrigerated at 2°C to 8°C (36°F to 46°F). When refrigerated, the contents may partially freeze. Allow the vial to reach room temperature (15°C to 30°C or 59°F to 86°F) prior to use. Observe the contents of the vial for any visible solid or particulate matter. Do not use the product if solid or particulate matter is observed after reaching room temperature.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Intravenous Infusion</content>
                        </paragraph>
                        <paragraph>Aseptically withdraw the volume needed for the required dose from the 25 mg/mL solution as per Table 1 below and immediately transfer to a <content styleCode="bold">250 mL infusion bag</content> of one of the following diluents: 0.9% Sodium Chloride Injection, USP; or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold"> The resulting final concentration of bendamustine hydrochloride in the infusion bag should be within 0.1 mg/mL to 1.36 mg/mL</content>.<br/> After transferring, thoroughly mix the contents of the infusion bag. The admixture should be a clear and colorless to slightly yellow solution.</paragraph>
                        <paragraph>
                           <content styleCode="bold">No other diluents have been shown to be compatible <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.4">2.4</linkHtml>)].</content>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Table 1: Volume of VIVIMUSTA required for <content styleCode="underline">Dilution into 250 mL</content> of 0.9% Sodium Chloride Injection, USP, or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP for a Given Dose and Body Surface Area</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="624">
                           <colgroup>
                              <col width="17.3076923076923%"/>
                              <col width="13.7820512820513%"/>
                              <col width="13.7820512820513%"/>
                              <col width="13.7820512820513%"/>
                              <col width="13.7820512820513%"/>
                              <col width="13.7820512820513%"/>
                              <col width="13.7820512820513%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" rowspan="2" align="center">
                                    <content styleCode="bold">Body Surface Area (m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="6" align="center">
                                    <content styleCode="bold">Volume of VIVIMUSTA to Withdraw (mL) from Vial</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">120 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">100 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">90 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">60 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">50 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">25 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                    <br/>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">1.1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1.1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">1.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1.2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">1.3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3.1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1.3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">1.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6.7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1.4<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">1.5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1.5<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">1.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7.7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1.6<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">1.7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6.1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1.7<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">1.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6.5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1.8<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">1.9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9.1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1.9<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">2.1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10.1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.1<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">2.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7.9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.2<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">2.3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8.3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.3<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">2.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11.5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.4<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">2.5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.5<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">2.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12.5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.6<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">2.7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">13<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9.7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6.5<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.7<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">2.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">13.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10.1<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6.7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.8<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">2.9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">13.9<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11.6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2.9<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">3<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14.4<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10.8<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7.2<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Discard any unused solution according to institutional procedures for hazardous drugs.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="b6390003-5afe-42e7-8c99-82cde6589559"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.4 Admixture Stability</title>
                     <text>
                        <paragraph>VIVIMUSTA contains no antimicrobial preservative. Prepare the admixture as close as possible to the time of patient administration.</paragraph>
                        <paragraph>Once diluted with 0.9% Sodium Chloride Injection, USP,  or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP, the final admixture is stable for 24 hours when stored refrigerated (2°C to 8°C or 36°F to 46°F) or for 3 hours when stored at room temperature (15°C to 30°C or 59°F to 86°F) and room light. Complete administration of diluted VIVIMUSTA within this period of time. <br/>
                           <br/> VIVIMUSTA (bendamustine hydrochloride injection) is supplied in a multiple-dose vial. Retain the partially used vial in original package to protect from light and store refrigerated (2°C to 8°C or 36°F to 46°F) if additional dose withdrawal from the same vial is intended.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.5">
                     <id root="9ba30009-a064-46ad-b066-4c2a9e05071d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.5 Stability of Partially Used Vials (Needle Punched Vials)</title>
                     <text>
                        <paragraph>VIVIMUSTA is supplied as a multiple-dose vial. Although it does not contain any antimicrobial preservative, VIVIMUSTA is bacteriostatic. The partially used vials are stable for up to 28 days when stored in its original carton under refrigeration (2°C to 8°C or 36°F to 46°F). Each vial is not recommended for more than a total of six (6) dose withdrawals.<br/>
                           <br/> After first use, store the partially used vial in the original carton at 2°C to 8°C (36°F to 46°F) and then discard after 28 days.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="ad524616-4eaa-418d-94ae-d7dc45960485"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS &amp; STRENGTHS</title>
               <text>
                  <paragraph>Injection: 100 mg/4 mL (25 mg/mL) as a clear and colorless to yellow solution in multiple-dose vial.</paragraph>
               </text>
               <effectiveTime value="20250328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 100 mg/4 mL (25 mg/mL) in a multiple-dose vial (<linkHtml href="#Section_3">3</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="a595d4fb-69f2-453b-aa7f-ce39a9ed5290"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>VIVIMUSTA is contraindicated in patients with a known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine, polyethylene glycol 400, dehydrated alcohol, or monothioglycerol <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>History of a hypersensitivity reaction to bendamustine, polyethylene glycol 400, dehydrated alcohol, or monothioglycerol. Reactions to bendamustine hydrochloride have included anaphylaxis and anaphylactoid reactions. (<linkHtml href="#Section_4">4</linkHtml>, <linkHtml href="#Section_5.4">5.4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="957550bb-a91e-41a0-9a33-31893bdfd97f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• <content styleCode="underline">Myelosuppression</content>: Delay or reduce dose, and restart treatment based on ANC and platelet count recovery. (<linkHtml href="#Section_5.1">5.1</linkHtml>)<br/> • <content styleCode="underline">Infections</content>: Monitor for fever and other signs of infection or reactivation of infections and treat promptly. (<linkHtml href="#Section_5.2">5.2</linkHtml>)</paragraph>
                        <paragraph>• <content styleCode="underline">Progressive multifocal leukoencephalopathy (PML)</content>: Monitor for new or worsening neurological, cognitive or behavioral signs or symptoms suggestive of PML. (<linkHtml href="#Section_5.3">5.3</linkHtml>)<br/> • <content styleCode="underline">Anaphylaxis and Infusion-Related Reactions</content>: Severe anaphylactic reactions have occurred. Monitor clinically and discontinue drug for severe reactions. Pre-medicate in subsequent cycles for milder reactions. (<linkHtml href="#Section_5.4">5.4</linkHtml>)<br/> • <content styleCode="underline">Tumor Lysis Syndrome</content>: May lead to acute renal failure and death; anticipate and use supportive measures in patients at high risk. (<linkHtml href="#Section_5.5">5.5</linkHtml>)<br/> • <content styleCode="underline">Skin Reactions</content>: Discontinue for severe skin reactions. Cases of SJS, DRESS and TEN, some fatal, have been reported. (<linkHtml href="#Section_5.6">5.6</linkHtml>).<br/> • <content styleCode="underline">Hepatotoxicity</content>: Monitor liver chemistry tests prior to and during treatment. (<linkHtml href="#Section_5.7">5.7</linkHtml>)<br/> • <content styleCode="underline">Other Malignancies</content>: Pre-malignant and malignant diseases have been reported. (<linkHtml href="#Section_5.8">5.8</linkHtml>)<br/> • <content styleCode="underline">Extravasation Injury</content>: Take precautions to avoid extravasation, including monitoring intravenous infusion site during and after administration. (<linkHtml href="#Section_5.9">5.9</linkHtml>)<br/> • <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of the potential risk to a fetus and to use an effective method of contraception. (<linkHtml href="#Section_5.10">5.10</linkHtml>,<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="a44fe5bc-f928-41b5-b963-b2747201306f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.1 Myelosuppression</title>
                     <text>
                        <paragraph>VIVIMUSTA causes myelosuppression. Bendamustine hydrochloride caused severe myelosuppression (Grade 3-4) in 98% of patients in the two NHL studies <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)]</content>. Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia and pneumonia from an opportunistic infection (CMV).<br/>
                           <br/> Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently. In the clinical trials, blood counts were monitored every week initially. Hematologic nadirs were observed predominantly in the third week of therapy. Myelosuppression may require dose delays and/or subsequent dose reductions if recovery to the recommended values has not occurred by the first day of the next scheduled cycle. Delay the next cycle of therapy if ANC less than 1 x 10<sup>9</sup>/L or platelet count less than 75 x 10<sup>9</sup>/L <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.1">2.1</linkHtml>, <linkHtml href="#Section_2.2">2.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="6108e40c-5f8a-4d6c-b0c4-48cf20d059b4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.2 Infections</title>
                     <text>
                        <paragraph>Infection, including pneumonia, sepsis, septic shock, hepatitis and death has occurred in adult and pediatric patients in clinical trials and in postmarketing reports for bendamustine hydrochloride [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>, <linkHtml href="#Section_6.2">6.2</linkHtml>)</content>]. Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections. Advise patients with myelosuppression following VIVIMUSTA treatment to contact healthcare provider immediately if they have symptoms or signs of infection.<br/>
                           <br/> Patients treated with VIVIMUSTA are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. Implement appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation prior to administration.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="6a384a2a-704c-4f44-b6ed-473198cd0ba6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.3 Progressive Multifocal Leukoencephalopathy (PML)</title>
                     <text>
                        <paragraph>Progressive multifocal leukoencephalopathy (PML), including fatal cases, have occurred following treatment with bendamustine, primarily in combination with rituximab or obinutuzumab<content styleCode="italics"> [see Adverse Reactions (<linkHtml href="#Section_6.2">6.2</linkHtml>)]</content>. Consider PML in the differential diagnosis in patients with new or worsening neurological, cognitive or behavioral signs or symptoms. If PML is suspected, withhold VIVIMUSTA treatment and perform appropriate diagnostic evaluations. Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="79f18b08-3445-4e2e-b983-1ec6e34dc1cd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.4 Anaphylaxis and Infusion-Related Reactions</title>
                     <text>
                        <paragraph>Infusion-related reactions to bendamustine hydrochloride have occurred commonly in clinical trials. Symptoms include fever, chills, pruritus and rash. In rare instances, severe anaphylactic and anaphylactoid reactions have occurred, particularly in the second and subsequent cycles of therapy. <br/>
                           <br/> Monitor clinically and discontinue drug for severe reactions. Ask patients about symptoms suggestive of infusion-related reactions after their first cycle of therapy. Do not rechallenge patients who experienced Grade 3 or worse allergic-type reactions. Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion-related reactions. Discontinue VIVIMUSTA for patients with Grade 4 infusion-related reactions. Consider discontinuation for Grade 3 infusion-related reactions as clinically appropriate considering individual benefits, risks, and supportive care.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="d50baa89-0896-4116-90b7-83e0ded32cc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.5 Tumor Lysis Syndrome</title>
                     <text>
                        <paragraph>Tumor lysis syndrome associated with bendamustine hydrochloride has occurred in patients in clinical trials and in postmarketing reports. The onset tends to be within the first treatment cycle of bendamustine hydrochloride and, without intervention, may lead to acute renal failure and death. <br/>
                           <br/> Administer vigorous hydration and monitor blood chemistry, particularly potassium and uric acid levels at baseline and closely during treatment with VIVIMUSTA. Allopurinol has also been used during the beginning of bendamustine hydrochloride therapy. However, there may be an increased risk of severe skin toxicity when bendamustine hydrochloride and allopurinol are administered concomitantly <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.6">5.6</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="55814003-d511-4a50-b9de-185c6cbdf4ce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.6 Skin Reactions</title>
                     <text>
                        <paragraph>Fatal and serious skin reactions have been reported with bendamustine hydrochloride treatment in clinical trials and postmarketing safety reports, including toxic skin reactions [Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS)], bullous exanthema, and rash. Events occurred when bendamustine hydrochloride was given as a single agent and in combination with other anticancer agents or allopurinol. Where skin reactions occur, they may be progressive and increase in severity with further treatment. </paragraph>
                        <paragraph>Monitor patients with skin reactions closely. If skin reactions are severe or progressive, withhold or discontinue VIVIMUSTA.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="6e77da5f-1067-490f-b194-14a3a9f29382"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.7 Hepatotoxicity</title>
                     <text>
                        <paragraph>Fatal and serious cases of liver injury have been reported with Bendamustine Hydrochloride Injection [see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)]. Combination therapy, progressive disease or reactivation of hepatitis B were confounding factors in some patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)].</content> Most cases were reported within the first three months of starting therapy. <br/>
                           <br/> Monitor liver chemistry tests prior to and during treatment with VIVIMUSTA.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.8">
                     <id root="5e65d5c8-951e-4fd5-a8ad-bffa18c39e05"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.8 Other Malignancies</title>
                     <text>
                        <paragraph>Pre-malignant and malignant diseases have developed in patients who have been treated with bendamustine hydrochloride, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia, bronchial carcinoma, and non-melanoma skin cancer including basal cell carcinoma and squamous cell carcinoma <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.2">6.2</linkHtml>)]</content>.<br/> Monitor patients for the development of secondary malignancies. Perform dermatologic evaluations during and after treatment with VIVIMUSTA.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.9">
                     <id root="10357391-bfa1-4cd9-b780-aba023172341"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.9 Extravasation Injury</title>
                     <text>
                        <paragraph>Bendamustine hydrochloride extravasations have been reported in postmarketing resulting in hospitalizations from erythema, marked swelling, and pain.<br/>
                           <br/> Assure good venous access prior to starting VIVIMUSTA infusion and monitor the intravenous infusion site for redness, swelling, pain, infection, and necrosis during and after administration of VIVIMUSTA.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.10">
                     <id root="66a3c640-3bf2-4d62-a403-88cd507d4817"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.10 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings from animal reproduction studies and the drug's mechanism of action, VIVIMUSTA can cause fetal harm when administered to a pregnant woman. Single intraperitoneal doses of bendamustine (that approximated the maximum recommended human dose based on body surface area) to pregnant mice and rats during organogenesis caused adverse developmental outcomes, including an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights. <br/>
                           <br/> Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with VIVIMUSTA and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with VIVIMUSTA and for 3 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3</linkHtml>) and Clinical Pharmacology (<linkHtml href="#Section_12.1">12.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="be5604cb-f6ac-4581-a88c-b1086a84b7a4"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labelling:<br/> • Myelosuppression <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>
                     <br/> • Infections <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">• </content>Progressive Multifocal Leukoencephalopathy<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics"/>• Anaphylaxis and Infusion-Related Reactions<content styleCode="italics">  [see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>
                     <br/> • Tumor Lysis Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.5">5.5</linkHtml>)]</content>
                     <br/> • Skin Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.6">5.6</linkHtml>)]</content>
                     <br/> • Hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.7">5.7</linkHtml>)]</content>
                     <br/> • Other Malignancies<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#Section_5.8">5.8</linkHtml>)]</content>
                     <br/> • Extravasation Injury <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.9">5.9</linkHtml>)]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• Adverse reactions (&gt; 5%) during infusion and within 24 hours post-infusion are nausea, and fatigue. (<linkHtml href="#Section_6.1">6.1</linkHtml>)<br/> • Most common adverse reactions (≥15%) for CLL are anemia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, hyperbilirubinemia, pyrexia, nausea, vomiting.  (<linkHtml href="#Section_6.1">6.1</linkHtml>)<br/> • Most common adverse reactions (≥15%) for NHL are lymphopenia, leukopenia, anemia neutropenia, thrombocytopenia, nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased dyspnea, rash, and stomatitis. (<linkHtml href="#Section_6.1">6.1</linkHtml>)<br/>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="229bfda3-e9e0-42e9-b523-7d4a97d538a9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br/>
                           <content styleCode="underline">Chronic Lymphocytic Leukemia (CLL)<br/>
                           </content>
                        </paragraph>
                        <paragraph>The data described below reflect exposure to bendamustine hydrochloride in 153 patients. Bendamustine hydrochloride was studied in an active-controlled, randomized trial. The population was 45-77 years of age, 63% were male, 100% were White, and had treatment naïve CLL. All patients started the study at a dose of 100 mg/m2 intravenously over 30 minutes on Days 1 and 2 every 28 days.<br/> Adverse reactions were reported according to NCI CTC v.2.0. In the randomized CLL clinical study, non-hematologic adverse reactions (any grade) in the bendamustine hydrochloride group that occurred with a frequency greater than 15% were pyrexia (24%), nausea (20%), and vomiting (16%). <br/> Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.</paragraph>
                        <paragraph>Worsening hypertension was reported in 4 patients treated with bendamustine hydrochloride and in none treated with chlorambucil. Three of these 4 adverse reactions were described as a hypertensive crisis and were managed with oral medications and resolved.</paragraph>
                        <paragraph>The most frequent adverse reactions leading to study withdrawal for patients receiving bendamustine hydrochloride were hypersensitivity (2%) and pyrexia (1%).</paragraph>
                        <paragraph>Table 2 summarizes the adverse reactions that were reported in ≥ 5% of patients in either treatment group in the randomized CLL clinical study.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2: Non-Hematologic Adverse Reactions that Occurred in at Least 5% of Patients Who Received Bendamustine Hydrochloride or Chlorambucil in the Randomized CLL Clinical Study</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="621">
                           <colgroup>
                              <col width="29.6774193548387%"/>
                              <col width="16.6129032258065%"/>
                              <col width="16.7741935483871%"/>
                              <col width="18.2258064516129%"/>
                              <col width="18.7096774193548%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2" valign="top">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" align="center" valign="middle">
                                    <content styleCode="bold">Bendamustine Hydrochloride</content>
                                    <br/>
                                    <content styleCode="bold">(N=153)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" align="center" valign="middle">
                                    <content styleCode="bold">Chlorambucil</content>
                                    <br/>
                                    <content styleCode="bold">(N=143)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                    <content styleCode="bold">n (%)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <br/>
                                    <content styleCode="bold">n (%)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                    <content styleCode="bold">n (%)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <br/>
                                    <content styleCode="bold">n (%)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Total number of patients with at least 1 adverse reaction</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold"/>
                                    <br/>
                                    <content styleCode="bold">121 (79)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold"/>
                                    <br/>
                                    <content styleCode="bold">52 (34)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold"/>
                                    <br/>
                                    <content styleCode="bold">96 (67)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold"/>
                                    <br/>
                                    <content styleCode="bold">25 (17)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Nausea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">31 (20)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1 (&lt;1)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">21 (15)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Vomiting<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">24 (16)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1 (&lt;1)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Diarrhea<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14 (9)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2 (1)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5 (3)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Pyrexia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">36 (24)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6 (4)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2 (1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Fatigue<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14 (9)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2 (1)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Asthenia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">13 (8)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6 (4)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Chills<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1 (&lt;1)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Immune system disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Hypersensitivity<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2 (1)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3 (2)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Infections and infestations</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Nasopharyngitis<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">10 (7)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12 (8)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Infection<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">9 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3 (2)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1 (&lt;1)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Herpes simplex<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5 (3)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Investigations</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Weight decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11 (7)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">5 (3)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Hyperuricemia<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">11 (7)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3 (2)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2 (1)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Cough<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6 (4)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1 (&lt;1)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Rash<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12 (8)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4 (3)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">7 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">3 (2)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Pruritus<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">8 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">2 (1)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">0<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> Hematology laboratory abnormalities are described in Table 3. Red blood cell transfusions were administered to 20% of patients receiving bendamustine hydrochloride compared with 6% of patients receiving chlorambucil. Bilirubin elevation occurred in 34% of patients, some without associated significant elevations in AST and ALT. Grade 3 or 4 increased bilirubin occurred in 3% of patients. Increases in AST and ALT of Grade 3 or 4 were limited to 1% and 3% of patients, respectively. Patients treated with bendamustine hydrochloride may also have changes in their creatinine levels.<br/>
                           <br/>
                           <content styleCode="bold">Table 3: Hematology Laboratory Abnormalities in Patients Who Received Bendamustine Hydrochloride or Chlorambucil in the Randomized CLL Clinical Study</content>
                        </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="624">
                           <colgroup>
                              <col width="20.48%"/>
                              <col width="20.48%"/>
                              <col width="20.48%"/>
                              <col width="20.48%"/>
                              <col width="18.08%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2" valign="top">
                                    <content styleCode="bold"> Laboratory</content>
                                    <br/>
                                    <content styleCode="bold">Abnormality</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" align="center" valign="middle">
                                    <content styleCode="bold">Bendamustine Hydrochloride </content>
                                    <br/>
                                    <content styleCode="bold">(N=150)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" align="center" valign="middle">
                                    <content styleCode="bold">Chlorambucil </content>
                                    <br/>
                                    <content styleCode="bold">(N=141)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">
                                    <content styleCode="bold">All Grades </content>
                                    <br/>
                                    <content styleCode="bold">n (%)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Grade 3 or 4 </content>
                                    <br/>
                                    <content styleCode="bold">n (%)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">All Grades </content>
                                    <br/>
                                    <content styleCode="bold">n (%)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Grade 3 or 4 </content>
                                    <br/>
                                    <content styleCode="bold">n (%)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Hemoglobin Decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">134 (89)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">20 (13)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">115 (82)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">12 (9)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Platelets Decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">116 (77)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">16 (11)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">110 (78)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">14 (10)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Neutrophils Decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">113 (75)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">65 (43)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">86 (61)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">30 (21)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Lymphocytes Decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">102 (68)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">70 (47)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">27 (19)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">6 (4)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Leukocytes Decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">92 (61)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">42 (28)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">26 (18)<br/>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">4 (3)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Non-Hodgkin Lymphoma (NHL)</content>
                        </paragraph>
                        <paragraph>The data described below reflect exposure to bendamustine hydrochloride in 176 patients with indolent B-cell NHL treated in two single-arm studies. The population was 31-84 years of age; 60% were male; 89% were White, 7% were Black, 3% were Hispanic, 1% were other, and &lt;1% were Asian. These patients received bendamustine hydrochloride at a dose of 120 mg/m<sup>2</sup> intravenously on Days 1 and 2 for up to eight 21-day cycles.<br/> In both studies, serious adverse reactions, were reported in 37% of patients receiving bendamustine hydrochloride. The most frequent serious adverse reactions occurring in ≥5% of patients were febrile neutropenia and pneumonia. Other important serious adverse reactions reported in clinical trials and/or postmarketing experience were acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, and myelodysplastic syndrome.<br/> Serious adverse reactions reported in clinical trials included myelosuppression, infection, pneumonia, tumor lysis syndrome and infusion-related reactions<content styleCode="italics"> [see Warnings</content>
                           <content styleCode="italics">and Precautions (<linkHtml href="#Section_5">5</linkHtml>)].</content> Adverse reactions occurring less frequently but possibly related to bendamustine hydrochloride treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.</paragraph>
                        <paragraph>The most common non-hematologic adverse reactions (≥30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%). The most common non-hematologic Grade 3 or 4 adverse reactions (≥5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.<br/> Non-hematologic adverse reactions are shown in Table 4.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 4: Non-Hematologic Adverse Reactions that Occurred in at Least 5% of Patients who Received Bendamustine Hydrochloride in the NHL Studies</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="638">
                           <colgroup>
                              <col width="56.5830721003135%"/>
                              <col width="22.5705329153605%"/>
                              <col width="20.846394984326%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule"> <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule" colspan="2">
                                    <content styleCode="bold">Bendamustine Hydrochloride <br/>             (N=176*)</content>
                                    <br/>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">All Grades <br/>             n(%)</content>
                                    <br/>
                                 </th>
                                 <th styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Grade</content>
                                    <content styleCode="bold">3 or 4 <br/>             n(%)</content>
                                    <br/>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Total number of patients with at least 1 adverse reaction</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">176 (100)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">94 (53)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Cardiac Disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Tachycardia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">13 (7)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3" valign="middle">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Nausea <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">132 (75) <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">7 (4)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Vomiting <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">71 (40)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">5 (3)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Diarrhea<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">65 (37)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">6 (3)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Constipation<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">51 (29)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Stomatitis<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">27 (15)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Abdominal pain<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">22 (13)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">2 (1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dyspepsia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">20 (11)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Gastroesophageal reflux disease<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">18 (10)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dry mouth<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">15 (9)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Abdominal pain upper<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">8 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Abdominal distension<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">8 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3" valign="middle">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Fatigue<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">101 (57)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">19 (11)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Pyrexia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">59 (34)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">3 (2)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Chills<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">24 (14)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Edema peripheral<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">23 (13)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Asthenia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">19 (11)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">4 (2)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Chest pain<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">11 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Infusion site pain<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">11 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Pain<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">10 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Catheter site pain<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">8 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Infections and infestations</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Herpes zoster<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">18 (10)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">5 (3)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Upper respiratory tract infection<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">18 (10)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Urinary tract infection<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">17 (10)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">4 (2)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Sinusitis<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">15 (9)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Pneumonia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">14 (8)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">9 (5)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Febrile neutropenia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">11 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">11 (6)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Oral candidiasis<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">11 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">2 (1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Nasopharyngitis<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">11 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Investigations</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Weight decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">31 (18)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">3 (2)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Anorexia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">40 (23)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">3 (2)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dehydration<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">24 (14)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">8 (5)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Decreased appetite<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">22 (13)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Hypokalemia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">15 (9)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">9 (5)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Back pain<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">25 (14)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">5 (3)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Arthralgia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">11 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Pain in extremity<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">8 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">2 (1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Bone pain<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">8 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Nervous system disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Headache<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">36 (21)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dizziness<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">25 (14)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dysgeusia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">13 (7)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Psychiatric disorder</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Insomnia<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">23 (13)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Anxiety<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">14 (8)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Depression<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">10 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Cough<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">38 (22)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dyspnea<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">28 (16)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">3 (2)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Pharyngolaryngeal pain<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">14 (8)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Wheezing<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">8 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Nasal congestion<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">8 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Rash<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">28 (16)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Pruritus<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">11 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dry skin<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">9 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Night sweats<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">9 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Hyperhidrosis<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">8 (5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Vascular disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Hypotension<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">10 (6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">2 (1)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">*Patients may have reported more than 1 adverse reaction.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">NOTE: </content>Patients counted only once in each preferred term category and once in each body system category.</paragraph>
                        <paragraph> Hematologic toxicities, based on laboratory values and CTC grade, in patients with NHL treated in both single arm studies combined are described in Table 5. Clinically important chemistry laboratory values that were new or worsened from baseline and occurred in &gt;1% of patients at grade 3 or 4, in patients with NHL who were treated in both single arm studies combined were hyperglycemia (3%), elevated creatinine (2%), hyponatremia (2%), and hypocalcemia (2%).<br/>
                           <br/>
                           <content styleCode="bold">Table 5: Hematology Laboratory Abnormalities in Patients Who Received Bendamustine Hydrochloride in the NHL Studies</content>
                        </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="840.56">
                           <colgroup>
                              <col width="32.5949367088608%"/>
                              <col width="33.7025316455696%"/>
                              <col width="33.7025316455696%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2" valign="middle">
                                    <content styleCode="bold">Hematology Variable</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle">
                                    <content styleCode="bold">Bendamustine Hydrochloride</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">All Grades <br/>             (%)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">Grade 3 or 4 <br/>             (%)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Lymphocytes Decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">99<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">94<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Leukocytes Decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">94<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">56<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Hemoglobin Decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">88<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">11<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Neutrophils Decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">86<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">60<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Platelets Decreased<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">86<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">25<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="17ca1a2e-7c29-4af5-82eb-b986be17524b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of bendamustine hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and lymphatic systems disorders:</content> Pancytopenia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular disorders:</content> Atrial fibrillation, congestive heart failure (some fatal), myocardial infarction (some fatal), palpitation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">General disorders and administration site conditions:</content> Injection site reactions (including phlebitis, pruritus, irritation, pain, swelling), infusion site reactions (including phlebitis, pruritus, irritation, pain, swelling).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorders:</content> Anaphylaxis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and infestations:</content> Pneumocystis jiroveci pneumonia, progressive multifocal leukoencephalopathy (PML).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and urinary disorders: </content>Nephrogenic diabetes insipidus (NDI)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, thoracic and mediastinal disorders:</content> Pneumonitis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders:</content> Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and non-melanoma skin cancer (NMSC).</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="6d5337cd-738c-4d6a-8eaf-d42c4b76712a"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with VIVIMUSTA. (<linkHtml href="#Section_7.1">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="1d1f5336-005f-4c62-9423-88505078d0bb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.1 Effect of Other Drugs on VIVIMUSTA</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">CYP1A2 Inhibitors</content>
                           <br/> The coadministration of VIVIMUSTA with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with VIVIMUSTA<content styleCode="italics"> [see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)].</content> Consider alternative therapies that are not CYP1A2 inhibitors during treatment with VIVIMUSTA.</paragraph>
                        <paragraph>
                           <content styleCode="underline">CYP1A2 Inducers</content>
                           <br/> The coadministration of VIVIMUSTA with CYP1A2 inducers may decrease bendamustine plasma concentrations and may result in decreased efficacy of VIVIMUSTA<content styleCode="italics"> [see</content>
                           <content styleCode="italics">Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)].</content>  Consider alternative therapies that are not CYP1A2 inducers during treatment with VIVIMUSTA.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="e34d8e4a-6ff6-4e74-ac4d-40821467800d"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250328"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#Section_8.2">8.2</linkHtml>)<br/> • <content styleCode="underline">Infertility</content>: May impair fertility. (<linkHtml href="#Section_8.3">8.3</linkHtml>)<br/> • <content styleCode="underline">Renal Impairment</content>: Do not use in patients with creatinine clearance &lt; 30 mL/min. (<linkHtml href="#Section_8.6">8.6</linkHtml>)<br/> • <content styleCode="underline">Hepatic Impairment</content>: Do not use in patients with total bilirubin 1.5-3 x ULN and AST or ALT 2.5-1.0 x ULN, or total bilirubin &gt; 3 x ULN. (<linkHtml href="#Section_8.7">8.7</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="37715c11-be9b-422f-a947-054f0442f26d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/> In animal reproduction studies, intraperitoneal administration of bendamustine to pregnant mice and rats during organogenesis at doses 0.6 to 1.8 times the maximum recommended human dose (MRHD) resulted in embryo-fetal and/or infant mortality, structural abnormalities, and alterations to growth <content styleCode="italics">(see Data).</content> There are no available data on bendamustine hydrochloride use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus.<br/>
                           <br/> The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.<br/>
                           <br/>
                           <content styleCode="underline">Data</content>
                           <br/>
                           <content styleCode="italics">Animal Data</content>
                           <br/> Bendamustine hydrochloride was intraperitoneally administered once to mice from 210 mg/m<sup>2</sup> (approximately 1.8 times the MRHD) during organogenesis and caused an increase in resorptions, skeletal and visceral malformations (exencephaly, cleft palates, accessory rib, and spinal deformities) and decreased fetal body weights. This dose did not appear to be maternally toxic and lower doses were not evaluated. Repeat intraperitoneal administration of bendamustine hydrochloride in mice on gestation days 7 to 11 resulted in an increase in resorptions from 75 mg/m<sup>2</sup> (approximately 0.6 times the MRHD) and an increase in abnormalities from 112.5 mg/m<sup>2</sup> (approximately 0.9 times the MRHD), similar to those seen after a single intraperitoneal administration.<br/>
                           <br/> Bendamustine hydrochloride was intraperitoneally administered once to rats from 120 mg/m<sup>2</sup> (approximately the MRHD) on gestation days 4, 7, 9, 11, or 13 and caused embryo and fetal lethality as indicated by increased resorptions and a decrease in live fetuses. A significant increase in external (effect on tail, head, and herniation of external organs [exomphalos]) and internal (hydronephrosis and hydrocephalus) malformations were seen in dosed rats.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="732455cb-20b9-467d-9efb-23459184e59d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/> There are no data on the presence of bendamustine hydrochloride or its metabolites in either human or animal milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with VIVIMUSTA and for 1 week after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.3">
                     <id root="fdd5bb3b-8759-40fc-8a36-43934b9cb673"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>VIVIMUSTA can cause embryo-fetal harm when administered to a pregnant woman <content styleCode="italics">[see </content>
                           <content styleCode="italics">Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>)].<br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                           <br/> Pregnancy testing is recommended for females of reproductive potential prior to initiation of treatment with VIVIMUSTA<content styleCode="italics">.<br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception<br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                           <br/> Advise female patients of reproductive potential to use effective contraception during treatment with VIVIMUSTA and for 6 months after the last dose. <br/>
                           <br/>
                           <content styleCode="italics">Males</content>
                           <br/> Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with VIVIMUSTA and for 3 months after the last dose [see <content styleCode="italics">Nonclinical Toxicology (<linkHtml href="#Section_13.1">13.1</linkHtml>)].</content>
                           <br/>
                           <br/>
                           <content styleCode="underline">Infertility</content>
                           <br/> Based on findings from clinical studies, VIVIMUSTA may impair male fertility. Impaired spermatogenesis, azoospermia, and total germinal aplasia have been reported in male patients treated with alkylating agents, especially in combination with other drugs. In some instances spermatogenesis may return in patients in remission, but this may occur only several years after intensive chemotherapy has been discontinued. Advise patients of the potential risk to their reproductive capacities. <br/>
                           <br/> Based on findings from animal studies, VIVIMUSTA may impair male fertility due to an increase in morphologically abnormal spermatozoa. The long-term effects of VIVIMUSTA on male fertility, including the reversibility of adverse effects, have not been studied [<content styleCode="italics">see Nonclinical Toxicology (<linkHtml href="#Section_13.1">13.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="603e0111-eacc-4c1a-b5cf-0d8f4a5550c4"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.<br/>
                           <br/> Safety, pharmacokinetics and efficacy were assessed in a single open-label trial (NCT01088984) in patients aged 1-19 years with relapsed or refractory acute leukemia, including 27 patients with acute lymphocytic leukemia (ALL) and 16 patients with acute myeloid leukemia (AML). <br/>
                           <br/> Bendamustine hydrochloride was administered as an intravenous infusion over 60 minutes on Days 1 and 2 of each 21-day cycle. There was no treatment response (CR+ CRp) in any patient. The safety profile in these patients was consistent with that seen in adults and no new safety signals were identified. <br/>
                           <br/> The pharmacokinetics of bendamustine in 43 patients, aged 1 to 19 years (median age of 10 years) were within range of values previously observed in adults given the same dose based on body surface area.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="a4980f7a-c46f-4d18-bbb3-f37068581b9d"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety were observed between patients ≥65 years of age and younger patients. Efficacy was lower in patients 65 and over with CLL receiving bendamustine hydrochloride based upon an overall response rate of 47% for patients 65 and over and 70% for younger patients. Progression free survival was also longer in younger patients with CLL receiving bendamustine (19 months vs. 12 months). No overall differences in efficacy in patients with non-Hodgkin Lymphoma were observed between geriatric patients and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="cd6d3ecb-48b7-4541-b597-a03bdacd9995"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Do not use VIVIMUSTA in patients with creatinine clearance (CLcr) less than 30 mL/min<content styleCode="italics"> [see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.7">
                     <id root="0f607b7b-ac5a-421d-b14c-388170e121d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>Do not use VIVIMUSTA in patients with AST or ALT 2.5 to 10 times upper limit of normal (ULN) and total bilirubin 1.5 to 3 times ULN or total bilirubin greater than 3 times ULN<content styleCode="italics"> [see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="6d96f475-d4a2-4976-b784-ac499af0371c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The intravenous lethal dose 50 (LD<sub>50</sub>) of bendamustine hydrochloride is 240 mg/m<sup>2</sup> in the mouse and rat. Toxicities included sedation, tremor, ataxia, convulsions and respiratory distress.<br/>
                     <br/> Across all clinical experience, the reported maximum single dose received was 280 mg/m<sup>2</sup>. Three of four patients who received this dose showed ECG changes considered dose-limiting at 7 and 21 days post-dosing. These changes included QT prolongation (one patient), sinus tachycardia (one patient), ST and T wave deviations (two patients) and left anterior fascicular block (one patient). Cardiac enzymes and ejection fractions remained normal in all patients.<br/>
                     <br/> No specific antidote for bendamustine hydrochloride overdose is known. Management of overdosage should include general supportive measures, including monitoring of hematologic parameters and ECGs.</paragraph>
               </text>
               <effectiveTime value="20250328"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="16f7e0fa-d643-42ec-bd5f-ca92527c0cbd"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Bendamustine hydrochloride is an alkylating agent. The chemical name of bendamustine hydrochloride monohydrate is 5-[Bis(2-chloroethyl)-amino]-1-methyl-1H-benzimidazole-2- butanoic acid hydrochloride monohydrate. Its empirical molecular formula is C<sub>16</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub> ∙ HCl.H<sub>2</sub>O and the molecular weight is 412.74. Bendamustine hydrochloride monohydrate contains a mechlorethamine group and a benzimidazole heterocyclic ring with a butyric acid substituent, and has the following structural formula:</paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM1"/>
                  <br/>
                  <paragraph>VIVIMUSTA (bendamustine hydrochloride injection) is intended for intravenous use after dilution with either 0.9% Sodium Chloride Injection, USP or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP. It is supplied as a sterile, clear, and colorless to yellow solution in a clear glass multiple-dose vial. Each milliliter contains 25 mg of bendamustine hydrochloride equivalent to 22.7 mg of bendamustine, 5 mg of monothioglycerol, 39.45 mg (5% v/v) of absolute alcohol, and q.s. to 1 mL polyethylene glycol 400. Sodium hydroxide is used to adjust pH of polyethylene glycol 400.</paragraph>
               </text>
               <effectiveTime value="20250328"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>VIVIMUSTA Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vivimusta-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="1624c554-b7ce-42b3-a3eb-e87945b51f68"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250328"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="aa5fbcf6-0ac3-426d-8ddb-fb1db2ae5dbd"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="474eb7e1-7f24-481a-9597-42cf083ad14b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Based on the pharmacokinetics/pharmacodynamics analyses of data from adult patients with NHL, nausea increased with increasing bendamustine maximum concentrations (C<sub>max</sub>).<br/>
                           <br/>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                           <br/> The effect of bendamustine on the QTc interval was evaluated in 53 patients with indolent NHL and mantle cell lymphoma on Day 1 of Cycle 1 after administration of rituximab at 375 mg/m<sup>2</sup> intravenous infusion followed by a 30-minute intravenous infusion of bendamustine at 90 mg/m<sup>2</sup>/day. No mean changes greater than 20 milliseconds were detected up to one hour post infusion. The potential for delayed effects on the QT interval after one hour was not evaluated.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="c1a2930b-b93e-420b-a68d-6e725ca39e11"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Following a single IV dose of bendamustine hydrochloride C<sub>max</sub> typically occurred at the end of infusion. The dose proportionality of bendamustine has not been studied. <br/>
                           <br/>
                           <content styleCode="underline">Distribution</content>
                           <br/> The protein binding of bendamustine ranged from 94-96% and was concentration independent from 1 to 50 μg/mL. The blood to plasma concentration ratios in human blood ranged from 0.84 to 0.86 over a concentration range of 10 to 100 μg/mL. <br/>
                           <br/> The mean steady-state volume of distribution (V<sub>ss</sub>) of bendamustine was approximately 20 to 25 L. <br/>
                           <br/>
                           <content styleCode="underline">Elimination</content>
                           <br/> After a single intravenous dose of 120 mg/m<sup>2 </sup>of bendamustine over 1 hour, the intermediate half-life (t<sub>½</sub>) of the parent compound was approximately 40 minutes. The mean terminal elimination t<sub>½</sub> of two active metabolites, γ-hydroxybendamustine (M3) and N desmethylbendamustine (M4) were approximately 3 hours and 30 minutes, respectively. Bendamustine clearance in humans was approximately 700 mL/min. <br/>
                           <br/>
                           <content styleCode="italics">Metabolism</content>
                           <br/> Bendamustine is extensively metabolized via hydrolytic, oxidative, and conjugative pathways. Bendamustine is primarily metabolized via hydrolysis to monohydroxy (HP1) and dihydroxy-bendamustine (HP2) metabolites with low cytotoxic activity in vitro. Two active minor metabolites, M3 and M4, are primarily formed via CYP1A2 in vitro. M3 and M4 concentrations of these metabolites in plasma are 1/10th and 1/100th that of the parent compound, respectively. <br/>
                           <br/>
                           <content styleCode="italics">Excretion</content>
                           <br/> Following intravenous infusion of radiolabeled bendamustine hydrochloride in patients with cancer, approximately 76% of the dose was recovered. Approximately 50% of the dose was recovered in the urine (3.3% unchanged) and approximately 25% of the dose was recovered in the feces. Less than 1% of the dose was recovered in the urine as M3 and M4, and less than 5% of the dose was recovered in the urine as HP2. <br/>
                           <br/>
                           <content styleCode="italics">
                              <content styleCode="underline">Specific Populations</content>
                           </content>
                           <br/> No clinically meaningful effects on the pharmacokinetics of bendamustine were observed based on age (31 to 84 years), sex, mild to moderate renal impairment (CLcr ≥ 30 mL/min), or hepatic impairment with total bilirubin 1.5 &lt; ULN and AST or ALT &lt; 2.5 × ULN. The effects of severe renal impairment (CLcr &lt; 30 mL/min), or hepatic impairment with total bilirubin 1.5 to 3 × ULN and AST or ALT 2.5 to 10 × ULN or total bilirubin &gt; 3 × ULN on the pharmacokinetics of bendamustine is unknown.<br/>
                           <br/>
                           <content styleCode="italics">Race/Ethnicity</content>
                           <br/> Exposures in Japanese subjects (n=6) were 40% higher than non-Japanese subjects receiving the same dose. The clinical importance of this difference on the safety and efficacy of bendamustine hydrochloride in Japanese subjects has not been established.<br/>
                           <br/>
                           <content styleCode="underline">Drug Interaction Studies<br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies<br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Bendamustine Hydrochloride on CYP Substrates: </content>Bendamustine hydrochloride did not inhibit CYP1A2, 2C9/10, 2D6, 2E1, or 3A4/5. Bendamustine hydrochloride did not induce metabolism of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Transporters on Bendamustine Hydrochloride:</content>Bendamustine hydrochloride is a substrate of P-glycoprotein and breast cancer resistance protein (BCRP).</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="659187aa-d106-4d13-83b2-7e6fece1d76d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250328"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="96816599-2e1f-4d61-8c2c-d0c8da0d1aad"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis &amp; Mutagenesis &amp; Impairment Of Fertility</title>
                     <text>
                        <paragraph>Bendamustine was carcinogenic in mice. After intraperitoneal injections at 37.5 mg/m<sup>2</sup>/day (the lowest dose tested, approximately 0.3 times the maximum recommended human dose [MRHD]) and 75 mg/m<sup>2</sup>/day (approximately 0.6 times the MRHD) for 4 days, peritoneal sarcomas in female AB/jena mice were produced. Oral administration at 187.5 mg/m<sup>2</sup>/day (the only dose tested, approximately 1.6 times the MRHD) for 4 days induced mammary carcinomas and pulmonary adenomas.<br/>
                           <br/> Bendamustine is a mutagen and clastogen. In a reverse bacterial mutation assay (Ames assay), bendamustine was shown to increase revertant frequency in the absence and presence of metabolic activation. Bendamustine was clastogenic in human lymphocytes in vitro, and in rat bone marrow cells in vivo (increase in micronucleated polychromatic erythrocytes) from 37.5 mg/m<sup>2</sup>, (the lowest dose tested, approximately 0.3 times the MRHD). <br/> Bendamustine induced morphologic abnormalities in spermatozoa in mice. Following tail vein injection of bendamustine at 120 mg/m<sup>2</sup> or a saline control on days 1 and 2 for a total of three weeks, the number of spermatozoa with morphologic abnormalities was 16% higher in the bendamustine-treated group as compared to the saline control group.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="217f2e7d-28bf-43fa-ac59-26d86dbb3094"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250328"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="7fa1013d-8243-4486-bb58-04bf1e8f3fb7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.1 Chronic Lymphocytic Leukemia (CLL)</title>
                     <text>
                        <paragraph>The efficacy of bendamustine hydrochloride was evaluated in an open-label, randomized, controlled multicenter trial comparing bendamustine hydrochloride to chlorambucil. The trial was conducted in 301 previously-untreated patients with Binet Stage B or C (Rai Stages I - IV) CLL requiring treatment. Need-to-treat criteria included hematopoietic insufficiency, B-symptoms, rapidly progressive disease or risk of complications from bulky lymphadenopathy. Patients with autoimmune hemolytic anemia or autoimmune thrombocytopenia, Richter’s syndrome, or transformation to prolymphocytic leukemia were excluded from the study. Patients were randomly assigned to receive either bendamustine hydrochloride 100 mg/m<sup>2</sup> intravenously over 30 minutes on Days 1 and 2 of each 28-day cycle or chlorambucil 0.8 mg/kg (Broca’s normal weight) orally on Days 1 and 15 of each 28-day cycle. <br/>
                           <br/> The patient populations in the bendamustine hydrochloride and chlorambucil treatment groups were balanced with regard to the following baseline characteristics: age (median 63 vs. 66 years), sex (63% vs. 61% male), Binet stage (71% vs. 69% Binet B), lymphadenopathy (79% vs. 82%), enlarged spleen (76% vs. 80%), enlarged liver (48% vs. 46%), hypercellular bone marrow (79% vs. 73%), “B” symptoms (51% vs. 53%), lymphocyte count (mean 65.7 x 10<sup>9</sup>/L vs. 65.1 x 10<sup>9</sup>/L), and serum lactate dehydrogenase concentration (mean 370.2 vs. 388.4 U/L). Ninety percent of patients in both treatment groups had immuno-phenotypic confirmation of CLL (CD5, CD23 and either CD19 or CD20 or both).<br/>
                           <br/> Efficacy endpoints of objective response rate and progression-free survival were calculated using a pre-specified algorithm based on NCI working group criteria for CLL. The results of this open-label randomized study demonstrated a higher rate of overall response and a longer progression-free survival for bendamustine hydrochloride compared to chlorambucil (<content styleCode="italics">see</content> Table 6). Survival data are not mature.<br/>
                           <br/>
                           <content styleCode="bold">Table 6: Efficacy Data for CLL</content>
                        </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="849.87">
                           <colgroup>
                              <col width="26.60406885759%"/>
                              <col width="27.6995305164319%"/>
                              <col width="28.9514866979656%"/>
                              <col width="16.7449139280125%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">Bendamustine Hydrochloride (N=153)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">Chlorambucil</content>
                                    <br/>
                                    <content styleCode="bold">(N=148)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">
                                    <content styleCode="bold"> p-value</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Response Rate n (%)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="3" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Overall response rate<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">90 (59)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">38 (26)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">&lt;0.0001<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">(95% CI)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">(51, 66.6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">(18.6, 32.7)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Complete response (CR)*<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">13 (8)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1 (&lt;1)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Nodular partial response (nPR)**<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">4 (3)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Partial response (PR) †<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">73 (48)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">37 (25)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Progression-Free Survival</content>††<br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="3" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Median, months (95% CI)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">18 (11.7, 23.5)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">6 (5.6, 8.6)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Hazard ratio (95% CI)<br/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="middle">0.27 (0.17, 0.43)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">&lt;0.0001<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>CI = confidence interval</paragraph>
                        <paragraph>*  CR was defined as peripheral lymphocyte count ≤ 4 x 109/L, neutrophils ≥ 1.5 x 109/L, platelets &gt;100 x 109/L, <br/>     hemoglobin &gt;110 g/L, without transfusions, absence of palpable hepatosplenomegaly, lymph nodes ≤ 1.5 cm, <br/>     &lt; 30% lymphocytes without nodularity in at least a normocellular bone marrow and absence of “B” symptoms. <br/>     The clinical and laboratory criteria were required to be maintained for a period of at least 56 days.</paragraph>
                        <paragraph>**  nPR was defined as described for CR with the exception that the bone marrow biopsy shows persistent nodules.<br/>†  PR was defined as ≥50% decrease in peripheral lymphocyte count from the pre-treatment baseline <br/>     value, and either ≥50% reduction in lymphadenopathy, or ≥50% reduction in the size of spleen or liver, <br/>     as well as one of the following hematologic improvements: neutrophils ≥ 1.5 x 109/L or 50% improvement over <br/>     baseline, platelets &gt;100 x 109/L or 50% improvement over baseline, hemoglobin &gt;110 g/L or 50% improvement <br/>     over baseline without transfusions, for a period of at least 56 days.<br/>†† PFS was defined as time from randomization to progression or death from any cause.<br/>
                           <br/>Kaplan-Meier estimates of progression-free survival comparing bendamustine hydrochloride with chlorambucil are shown in Figure 1.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Figure 1. Progression-Free Survival</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                        <br/>
                     </text>
                     <effectiveTime value="20250328"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>figure-1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="a0a9f409-efec-4789-8e46-ebcc16c568a9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.2 Non-Hodgkin Lymphoma (NHL)</title>
                     <text>
                        <paragraph>The efficacy of bendamustine hydrochloride was evaluated in a single arm study of 100 patients with indolent B-cell NHL that had progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Patients were included if they relapsed within 6 months of either the first dose (monotherapy) or last dose (maintenance regimen or combination therapy) of rituximab. All patients received bendamustine hydrochloride 120 mg/m<sup>2 </sup>intravenously on Days 1 and 2 of a 21-day treatment cycle for up to 8 cycles.<br/>
                           <br/> The median age was 60 years, 65% were male, and 95% had a baseline WHO performance status of 0 or 1. Major tumor subtypes were follicular lymphoma (62%), diffuse small lymphocytic lymphoma (21%), and marginal zone lymphoma (16%). Ninety-nine percent of patients had received previous chemotherapy, 91% of patients had received previous alkylator therapy, and 97% of patients had relapsed within 6 months of either the first dose (monotherapy) or last dose (maintenance regimen or combination therapy) of rituximab.<br/>
                           <br/> Efficacy was based on the assessments by a blinded independent review committee (IRC) and included overall response rate (complete response + complete response unconfirmed + partial response) and duration of response (DR) as summarized in Table 7.<br/>
                           <br/>
                           <content styleCode="bold">Table 7: Efficacy Data for NHL*</content>
                        </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="599.83">
                           <colgroup>
                              <col width="54.7671840354767%"/>
                              <col width="45.2328159645233%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle"> <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">Bendamustine Hydrochloride (N=100)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Response Rate (%)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Overall response rate (CR+CRu+PR)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">74<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">(95% CI)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">(64.3, 82.3)<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Complete response (CR)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">13<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Complete response unconfirmed (CRu)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">4<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Partial response (PR)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">57<br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Duration of Response (DR)</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle"> <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Median, months (95% CI)<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">9.2 months (7.1, 10.8)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> CI = confidence interval<br/> *IRC assessment was based on modified International Working Group response criteria (IWG-RC). Modifications to IWG-RC specified that a persistently positive bone marrow in patients who met all other criteria for CR would be scored as PR. Bone marrow sample lengths were not required to be ≥20 mm.</paragraph>
                     </text>
                     <effectiveTime value="20250328"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_15">
               <id root="158b0d0a-7fcf-47ea-bdd7-6df751b3b22a"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1. OSHA Hazardous Drugs. <content styleCode="italics">OSHA</content>. https://www.osha.gov/hazardous-drugs</paragraph>
               </text>
               <effectiveTime value="20250328"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="9bb6b13a-4936-477e-beb3-224e8f985fa5"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                     <br/> VIVIMUSTA (bendamustine hydrochloride injection) is a sterile clear, colorless to yellow solution for intravenous use supplied in individual cartons of multiple-dose vials providing 100 mg bendamustine hydrochloride per 4 mL.</paragraph>
                  <paragraph>100 mg/4 mL (25 mg/mL)  NDC 24338-270-01<br/>
                     <br/>
                     <content styleCode="underline">Safe Handling and Disposal</content>
                  </paragraph>
                  <paragraph>VIVIMUSTA (bendamustine hydrochloride injection) is a hazardous drug. Follow applicable special handling and disposal procedures<sup>1</sup>. Care should be exercised in the handling and preparation of solutions prepared from VIVIMUSTA. The use of gloves and safety glasses is recommended to avoid exposure in case of breakage of the vial or other accidental spillage. If gloves come in contact with VIVIMUSTA prior to dilution, remove gloves and follow disposal procedures. If a solution of VIVIMUSTA (bendamustine hydrochloride injection) contacts the skin, wash the skin immediately and thoroughly with soap and water. If VIVIMUSTA (bendamustine hydrochloride injection) contacts the mucous membranes, flush thoroughly with water.<br/>
                     <br/>
                     <content styleCode="underline">Storage</content>
                  </paragraph>
                  <paragraph>Store VIVIMUSTA (bendamustine hydrochloride injection) refrigerated at 2°C to 8°C (36°F to 46°F). Retain in original carton until time of use to protect from light.</paragraph>
               </text>
               <effectiveTime value="20250328"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="30fa85f2-c058-4411-872a-1334ba0861d3"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Myelosuppression</content>
                     <br/> Inform patients of the likelihood that bendamustine hydrochloride will cause a decrease in white blood cells, platelets, and red blood cells and the need for frequent monitoring of blood counts. Advise patients to report shortness of breath, significant fatigue, bleeding, fever, or other signs of infection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics"> </content>
                     <br/>
                     <content styleCode="underline">Progressive Multifocal Leukoencephalopathy (PML)</content>
                     <br/> Inform patients to immediately contact their healthcare provider if they experience confusion, memory loss, trouble thinking, difficulty talking or walking, vision loss or other neurological or cognitive symptoms<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)</content>].</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Anaphylaxis and Infusion-Related Reactions</content>
                     <br/>Inform patients of the possibility of serious or mild allergic reactions and to immediately report rash, facial swelling, or difficulty breathing during or soon after infusion<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)].<br/>
                     </content>
                     <br/>
                     <content styleCode="underline">Skin Reactions</content>
                     <br/> Advise patients that a rash or itching may occur during treatment with VIVIMUSTA. Advise patients to immediately report severe or worsening rash or itching<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#Section_5.6">5.6</linkHtml>)]</content>.<br/>
                     <br/>
                     <content styleCode="underline">Hepatotoxicity</content>
                     <br/> Inform patients of the possibility of developing liver function abnormalities and serious hepatic toxicity. Advise patients to immediately contact their healthcare provider if signs of liver failure occur, including jaundice, anorexia, bleeding or bruising <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.7">5.7</linkHtml>)]</content>.<br/>
                     <br/>
                     <content styleCode="underline">Fatigue</content>
                     <br/> Advise patients that VIVIMUSTA may cause tiredness and to avoid driving any vehicle or operating any dangerous tools or machinery if they experience this side effect <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)].</content>
                     <br/>
                     <br/>
                     <content styleCode="underline">Nausea and Vomiting</content>
                     <br/> Advise patients that VIVIMUSTA may cause nausea and/or vomiting. Patients should report nausea and vomiting so that symptomatic treatment may be provided <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)].</content>
                     <br/>
                     <br/>
                     <content styleCode="underline">Diarrhea</content>
                     <br/> Advise patients that VIVIMUSTA may cause diarrhea. Patients should report diarrhea to the healthcare provider so that symptomatic treatment may be provided <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics"> </content>
                     <br/>
                     <content styleCode="underline">Non-melanoma Skin Cancer (NMSC)</content>
                     <br/> Advise patients to undergo regular skin cancer screenings, and to report any suspicious skin changes to their healthcare provider<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#Section_5.8">5.8</linkHtml>)]</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                     <br/> Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.10">5.10</linkHtml>), Use in</content>
                     <content styleCode="italics">Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3</linkHtml>), and Nonclinical Toxicology (<linkHtml href="#Section_13.1">13.1</linkHtml>)].</content>
                     <br/>
                     <br/> Advise female patients of reproductive potential to use effective contraception during treatment with VIVIMUSTA and for 6 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.3">8.3</linkHtml>)].</content>
                     <br/>
                     <br/> Advise males with female partners of reproductive potential to use effective contraception during treatment with VIVIMUSTA and for 3 months after the last dose <content styleCode="italics">[see Use in Specific Populations (8.3) and Nonclinical Toxicology (<linkHtml href="#Section_13.1">13.1</linkHtml>)].</content>
                     <br/>
                     <br/>
                     <content styleCode="underline">Lactation</content>
                     <br/> Advise females not to breastfeed during treatment with VIVIMUSTA and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.2">8.2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                     <br/> Advise males of reproductive potential that VIVIMUSTA may impair fertility <content styleCode="italics"> [see Use in Specific Populations (<linkHtml href="#Section_8.3">8.3</linkHtml>)].</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <paragraph>Manufactured for:<br/>Azurity Pharmaceuticals, Inc.<br/>Woburn, MA 01801 USA<br/> </paragraph>
                  <paragraph> Vivimusta<sup>®</sup> is a trademark of Azurity Pharmaceuticals, Inc.<br/>
                     <br/>Manufactured at:<br/>Latina Pharma S.p.A.<br/>04013 Sermoneta (LT), Italy.<br/> </paragraph>
                  <br/>
                  <paragraph>Rev. MAR2025<br/>VIV-PI-PE1-01</paragraph>
               </text>
               <effectiveTime value="20250328"/>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="bc6d8fd3-249f-419c-873b-1c5f3e968b2e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">
                           <content styleCode="bold">Principal Display Panel -</content> Carton Label <br/>
                        </content>
                        <content styleCode="bold">NDC 24338-270-01</content>
                        <br/> VIVIMUSTA<sup>®</sup> (bendamustine hydrochloride injection) </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mg/4mL (25 mg/mL)<br/>
                     </content>
                  </paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM3"/>
                  <br/>
                  <br/>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel - Vial Label <br/> NDC <content styleCode="bold">24338-270-01</content>
                     </content>
                  </paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">VIVIMUSTA<sup>®</sup> (bendamustine hydrochloride injection)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mg/4mL (25 mg/mL)</content>
                  </paragraph>
                  <paragraph>  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <br/>
               </text>
               <effectiveTime value="20250329"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Vivimusta Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vivimusta-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Vivimusta vial</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vivimusta-vial.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>